ClinicalTrials.gg
Enrolling by invitationNCT05786534Updated Sep 29, 2023

Therapeutic Effect of Green Seaweed Against Metabloc Syndrome

An interventional study of Green Seaweed in Metabolic Syndrome, sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 35 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2023, 3 years ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
35 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Metabolic Syndrome with a site in Pakistan — 6 open to participants now, 7 under way, none of them phase 3. Metabolic Syndrome · Pakistan.

Planned enrollment
13th of 16
40 · median 60
Started
2022
the only one that year
No phase
14 of 16
6 open now
Registered
4th of 16
by date
Lead sponsor
4 of 16
University of Veterinary and Animal Sciences, Lahore - Pakistan

Among the 16 studies in Metabolic Syndrome with a site in Pakistan, this one is the 13th largest by planned enrollment, is the only one that started in 2022, is one of 14 with no phase, and was the 4th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

6 of the 16 studies in Metabolic Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 35 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Metabolic Syndrome with a site in Pakistan, or all of them as a file.
02

Study summary

Metabolic syndrome is a major concern worldwide and in Pakistan as well. Metabolic syndrome is a pathologic condition which includes abdominal obesity, insulin resistance, hypertension and hyperlipidemia. Seafood consumption has been linked to reduced risk of many health conditions including altered blood profile. Green seaweed is known to have a potential in optimizing the blood profile and so, it is helpful in reducing the risk of metabolic syndrome by playing a role in preventing obesity, hyperglycemia, high blood pressure and altered lipid profile. Green seaweed (Ulva Lactuca) powder will prove to have therapeutic potential against obesity, hypertension, glucose intolerance and dyslipidemia.

Read the detailed description

Metabolic syndrome is a major concern worldwide and in Pakistan as well. Metabolic syndrome is a pathologic condition which includes abdominal obesity, insulin resistance, hypertension and hyperlipidemia. Seafood consumption has been linked to reduced risk of many health conditions including altered blood profile. Green seaweed is known to have a potential in optimizing the blood profile and so, it is helpful in reducing the risk of metabolic syndrome by playing a role in preventing obesity, hyperglycemia, high blood pressure and altered lipid profile.

Statement of problem: The number of people with high LDL-cholesterol, body mass index and fasting plasma glucose levels has been increasing. These factors are promoting the risk of metabolic syndrome in Pakistan. 26-38% people in Pakistan are reported to be a patient of metabolic syndrome. Seaweed has shown to be protective against the syndrome in previous studies. The goal of this study is to check the role of green seaweed against metabolic syndrome.

Hypothesis: Green seaweed (Ulva Lactuca) has a potential to manage metabolic syndrome.

Objective: To assess the therapeutic effect of green seaweed (Ulva Lactuca) against metabolic syndrome.

Methodology: Green seaweed powder will be procured from Taokaenoi Food and Marketing Public Co., Ltd. (Thailand). The proximate analysis of the product will be performed and then capsules of powder will be prepared to be consumed by the participants. Total 40 subjects (20 in treatment group and 20 in control group) will be selected and green seaweed powder will be added in their diets (200mg twice a day). After a trial of 40 days, the patients will be assessed. Assessment will include anthropometric measurements, blood pressure, lipid profile analysis and total antioxidant capacity (TAC) which will be monitored before and after the trial and final,ly, the data collected will be analyzed by using SPSS 25 by paired sample t test. P value ≤ 0.05 will be considered significant.

Expected outcomes: Green seaweed (Ulva Lactuca) powder will prove to have therapeutic potential against obesity, hypertension, glucose intolerance and dyslipidemia.

03

Conditions studied

  • Metabolic Syndrome

Keywords

  • Metabolic Syndrome
  • Hypertension
  • Diabetes
  • Obesity
  • Dyslipidemia
  • Seaweed
04

Who can participate

Ages eligible
35 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 25kg/m2
  • Dyslipidemia
  • Altered blood glucose level
  • Age 30-55 ( male and female)

Exclusion criteria

Exclusion Criteria:

  • Thyroid disorder
  • Liver disease
  • Kidney disorder
  • Cancer etc
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Metabolic Syndrome patients

    Green seaweed Ulva Lactuca is used for preventing symptoms in Metabolic Syndrome patients

    Dietary Supplement: Green Seaweed

Interventions

  • Dietary supplementGreen Seaweed

    400 mg per day

    Also known as: Ulva Lactuca

06

What researchers measure

Primary outcomes

  1. Blood pressure will be assessed before and after the trial

    The change in blood pressure, after consuming green seaweed powder for 40 days, will be assessed. The values will become close to optimized levels.

    Time frame: 40 days

  2. Lipid profile will be assessed before and after the trial

    The improvement in lipid profile, after consuming green seaweed powder for 40 days, will be assessed. The values will become close to optimized values.

    Time frame: 40 days

  3. Fasting glucose level will be assessed before and after the trial

    The change in fasting glucose levels will be assessed, after consuming green seaweed powder for 40 days. The values will become close to optimized levels.

    Time frame: 40 days

  4. Weight will be measured before and after the trial

    The change in weight will be measured, after consuming green seaweed powder for 40 days. BMI will become close to normal range.

    Time frame: 40 days

07

Study locations

1 site
  • Ashraf Hospital
    Gujrānwāla, Punjab 52250, Pakistan
08

References and documents

Publications

  • Cardoso SM, Pereira OR, Seca AM, Pinto DC, Silva AM. Seaweeds as Preventive Agents for Cardiovascular Diseases: From Nutrients to Functional Foods. Mar Drugs. 2015 Nov 12;13(11):6838-65. doi: 10.3390/md13116838. PubMed 26569268 ↗

Individual participant data

Plan to share: No — All available data will be confidential

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Nov 2023, 11 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 11 months is below that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2023
First posted
Mar 27, 2023
StartActual
Dec 9, 2022
Primary completionEst.
Nov 10, 2023
CompletionEst.
Nov 10, 2023
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05786534
Lead sponsor
University of Veterinary and Animal Sciences, Lahore - Pakistan
Responsible party
Asif Ali (Researcher, University of Veterinary and Animal Sciences, Lahore - Pakistan) — Principal investigator
First posted
Mar 27, 2023
Start date
Dec 9, 2022
Primary completion
Nov 10, 2023 (estimated)
Completion
Nov 10, 2023 (estimated)
Last update
Sep 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion